NCT04885426

Metformin for the Prevention of CRA Recurrence

The Role of Metformin in the Prevention for Colorectal Adenoma Recurrence in Post-polypectomy Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 414 (estimated)
• Sponsor: Jing-yuan Fang, MD, Ph. D · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.

Detailed description

Colorectal adenomas are well-known to be precancerous lesions that develop into colorectal cancers on the basis of the adenoma-carcinoma sequence. The effects of screening for colorectal adenomas and removing precancerous lesions on the prevention of colorectal cancer have been established. Because of the high recurrence rates of colorectal adenomas in patients who have undergone polypectomy, the potential chemopreventive agents that may reduce the risk of colorectal adenoma recurrence need to be investigated. Metformin is a widely used diabetes medicine. In recent years, anticancer activity of metformin has been explored. The aim of this study is to investigate the effect of metformin on the recurrence of colorectal adenomas by conducting a randomized, placebo-controlled, prospective clinical.

Conditions

• Colorectal Adenoma
• Metformin
• Chemoprevention

Interventions

Type	Name	Description
DRUG	low-dose metformin	Metformin Pill 250mg/day
DRUG	high-dose metformin	Metformin Pill 500mg/day
DRUG	Placebo	Placebo

Timeline

• Start date: 2020-08-01
• Primary completion: 2022-11-01
• Completion: 2022-11-01
• First posted: 2021-05-13
• Last updated: 2021-05-13

Locations

1 site across 1 country: China